MindMed’s (MNMD) Nasdaq debut Tuesday made it the second psychedelic drug developer to be listed on a major U.S. stock exchange. UK-based Compass Pathways (CMPS) went public on the Nasdaq in September, while last week Peter Thiel-backed ATAI Life Sciences filed for an IPO. Just a year ago, New York-based MindMed was a penny stock on the over-the-counter market. Shares fell 29% in their first day of trading on the Nasdaq, but that’s after they ran up 65% Friday and 33% Monday on the OTCQB… Source link
Read More »Psychedelic drugmaker MindMed stumbles in Nasdaq debut, CEO says ‘still very early innings’
